Bacteriophage-based Vaccine: A New Dawn for Vaccine Design and Development
Bacteriophage-based Vaccine for Vaccine Design and Development
DOI:
https://doi.org/10.53560/PPASB(60-sp1)835Keywords:
Antigen delivery, Bacteriophage, COVID-19, VaccineAbstract
The COVID-19 epidemic has strained healthcare systems, causing stress among personnel and facing significant economic and social issues. COVID-19 patients have significant symptoms, necessitating prompt treatment. It is a global urgency to develop effective vaccinations against COVID-19. Quick immunization of the whole world population against an ever-changing, extremely deadly virus is alarming, and various vaccine techniques are being researched. Bacteriophages are helpful in the treatment of multidrug-resistant bacterial infections. But, their clinical efficacy may go far beyond. One of the most significant bioproducts in medicine is thought to be vaccines. Vaccines for a variety of diseases have been made. However, certain vaccinations have disadvantages, such as high prices and immunological responses. In this regard, the use of bacteriophages has been suggested as an exciting alternative for making more inexpensive vaccines. Bacteriophage-displayed vaccines are based on the antigens being expressed on the phage surface. This tactic uses the inherent advantages of these particles, including their high stability, inexpensive production, and adjuvant capacity. Phage-displayed, phages DNA and hybrid phage-DNA vaccines are the three phage-based vaccines that are currently offered. The traditional method for finding novel barrier protection epitopes, antigens, and mimotopes is phage display. In this frame of reference, phage particles serve as a versatile, effective, and promising strategy for making vaccine delivery systems that are more effective and should be widely applied in the future. The phage-vaccine technique can potentially address the growing demand for innovative vaccinations against emerging diseases. This short communication addresses bacteriophage uses in vaccine development and discusses recent developments in bacteriophage-based vaccinations. It also focuses on and describes bacteriophages as a novel vaccine candidate for COVID-19.
References
B. Loh, V.S. Gondil, P. Manohar, F.M. Khan, H. Yang, and S. Leptihn. Encapsulation and delivery of therapeutic phages. Applied and Environmental Microbiology 87: e01979-20 (2021).
N. Brown, and C. Cox. Bacteriophage use in molecular biology and biotechnology. In: Bacteriophages: Biology, Technology, Therapy. D.R. Harper, S.T. Abedon, B.H. Burrowes, & M.L. McConville (Ed.) Springer, Cham. p. 465-506 (2021).
L. Aghebati-Maleki, B. Bakhshinejad, B. Baradaran, M. Motallebnezhad, A. Aghebati-Maleki, H. Nickho, M. Yousefi, and J. Majidi. Phage display as a promising approach for vaccine development. Journal of Biomedical Science 23: 1-18 (2016).
B. Greenwood. The contribution of vaccination to global health: past, present and future. Philosophical Transactions of the Royal Society B: Biological Sciences 369: 20130433 (2014).
S. Jorge, and O.A. Dellagostin. The development of veterinary vaccines: a review of traditional methods and modern biotechnology approaches. Biotechnology Research and Innovation 1: 6-13 (2017).
S. Rahman, M. Din, S. Khan, L. Yar, F. Zia, M. Idrees, and M. Ali. COVID-19 Vaccines: Pakistan’s Perspective. Proceedings of the Pakistan Academy of Sciences: B. Life and Environmental Sciences 58: 11-17 (2021).
J. Nicastro, K. Sheldon, and R.A. Slavcev. Bacteriophage lambda display systems: developments and applications. Applied Microbiology and Biotechnology 98: 2853-2866 (2014).
S. Adhya, C.R. Merril, and B. Biswas. Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold Spring Harbor Perspectives in Medicine 4: a012518 (2014).
J. Morales, J.J. Martínez, K. Manoutcharian, M. Hernández, A. Fleury, G. Gevorkian, G. Acero, A. Blancas, A. Toledo, and J. Cervantes. Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis. Vaccine 26: 23 2899-2905 (2008).
J. Nicastro, K. Sheldon, and R.A. Slavcev Bacteriophage lambda display systems: developments and applications. Applied Microbiology and Biotechnology 98: 2853-2866 (2014).
T.I. Samoylova, M.D. Norris, A.M. Samoylov, A.M. Cochran, K.G. Wolfe, V.A. Petrenko, and N.R. Cox. Infective and inactivated filamentous phage as carriers for immunogenic peptides. Journal of Virological Methods 183: 63-68 (2012).
J. Zhu, S. Jain, J. Sha, H. Batra, N. Ananthaswamy, P.B. Kilgore, E.K. Hendrix, Y.M. Hosakote, X. Wu, and J.P. Olano. A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine. MBio 13: e01822-22 (2022).
A.G. Mora, J.H. Pérez, H.M. Iqbal, M.R. Palomares and J. Benavides. Bacteriophage-based vaccines: A potent approach for antigen delivery. Vaccines 8: 504 (2020).
K.L. Hess, and C.M. Jewell. Phage display as a tool for vaccine and immunotherapy development. Bioengineering and Translational Medicine 5: e10142 (2020).
K. Manoutcharian. Bacteriophages as tools for vaccine and drug development. Expert Review of Vaccines 4: 5-7 (2005).
J. Zhu, N. Ananthaswamy, S. Jain, H. Batra, W.C. Tang, D.A. Lewry, M.L. Richards, S.A. David, P.B. Kilgore, and J. Sha. A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering. Science Advances 7: eabh1547 (2021).
P. Tao, M. Mahalingam, J. Zhu, M. Moayeri, J. Sha, W.S. Lawrence, S.H. Leppla, A.K. Chopra, and V.B. Rao. A bacteriophage T4 nanoparticle-based dual vaccine against anthrax and plague. MBio 9: e01926-18 (2018).
M. Li, P. Guo, C. Chen, H. Feng, W. Zhang, C. Gu, G. Wen, V.B. Rao, and P. Tao. Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development. Frontiers in Immunology 4256 (2021).
Q. Bao, X. Li, G. Han, Y. Zhu, C. Mao, and M. Yang. Phage-based vaccines. Advanced Drug Delivery Reviews 145: 40-56 (2019).
E.N. Woods. Viral Sensation. CatholicU Magazine, Fall 2021 (2021). https://communications.catholic.edu/magazine/fall-2021/viral-sensation.html
C. Fougeroux, L. Goksøyr, M. Idorn, V. Soroka, S.K. Myeni, R. Dagil, C.M. Janitzek, M. Søgaard, K.L. Aves, and E.W. Horsted. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nature Communications 12: 324 (2021).
M. Palma. Aspects of Phage-Based Vaccines for Protein and Epitope Immunization. Vaccines 11: 436 (2023).
A. Algazi, W. Smith, T. Panella, D. Shin, M.L. Fjaellskog, J. Celebi, A. Drumheller, J. Campbell, R. Pierce, and M. Guarino. 349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). Journal for ImmunoTherapy of Cancer 8: 349 (2020).
T. Anand, N. Virmani, B.C. Bera, R.K. Vaid, M. Vashisth, P. Bardajatya, A. Kumar, and B.N. Tripathi. Phage display technique as a tool for diagnosis and antibody selection for coronaviruses. Current Microbiology 78: 1124-1134 (2021).
C.R. de Vries, Q. Chen, S. Demirdjian, G. Kaber, A. Khosravi, D. Liu, J.D. Van Belleghem, and P.L. Bollyky. Phages in vaccine design and immunity; mechanisms and mysteries. Current Opinion in Biotechnology 68: 160-165 (2021).
Downloads
Published
How to Cite
Issue
Section
License
Creative Commons Attribution (CC BY). Allows users to: copy the article and distribute; abstracts, create extracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: includes a link to the license; indicates if changes were made; gives appropriate credit to the author(s) (with a link to the formal publication through the relevant DOI); and does not represent the author(s) as endorsing the adaptation of the article or modify the article in such a way as to damage the authors' honor or reputation.
